Important Information for ESSA Pharma Securities Purchasers: Deadline for Lead Plaintiff Application Approaches
New York, NY, March 6, 2025 – Rosen Law Firm, a global investor rights law firm, alerts investors who purchased securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, both dates inclusive (the “Class Period”), of the important deadline approaching for lead plaintiff application in a securities class action lawsuit. The lawsuit alleges that ESSA Pharma and certain of its top executives made false and/or misleading statements and/or failed to disclose material information about the company’s business, operations, and financial condition.
What Happened?
According to the lawsuit, the defendants made false and/or misleading statements and/or failed to disclose material information, including:
- Statements regarding the commercial prospects of ESSA Pharma’s lead product candidate, SEL212, for the treatment of hypogonadotropic hypogonadism (HH)
- Statements regarding the timing and likelihood of regulatory approvals for SEL212
- Statements regarding the company’s financial condition and prospects
These allegations came to light on October 31, 2024, when the company issued a press release announcing the delay of a key regulatory filing, which sent the price of ESSA Pharma securities tumbling down. The lawsuit was then filed on behalf of investors who purchased ESSA Pharma securities during the Class Period.
What Does This Mean for Investors?
If you purchased ESSA Pharma securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is fast approaching, and investors should contact Rosen Law Firm before March 25, 2025 to learn more about the case and how they can help. The law firm represents investors in securities fraud class actions and has recovered hundreds of millions of dollars for investors.
What Does This Mean for the World?
The securities class action lawsuit against ESSA Pharma is an important reminder of the need for transparency and accuracy in the public disclosures made by publicly traded companies. In an era where investors increasingly rely on digital channels for information, it is crucial that companies provide accurate and timely information to the investing public. The lawsuit also highlights the role of investor rights law firms in holding companies accountable for their actions and protecting the interests of investors.
Conclusion
If you purchased ESSA Pharma securities during the Class Period and believe that you may have lost money as a result of the alleged securities fraud, you may be entitled to compensation. Contact Rosen Law Firm before March 25, 2025 to learn more about the case and how you can help. The firm represents investors in securities fraud class actions and has a proven track record of recovering significant damages for investors. The lawsuit against ESSA Pharma underscores the importance of transparency and accuracy in corporate disclosures and the role of investor rights law firms in protecting investors.
